VICTORIA SPECIAN: Open Payments
NPI 1720132012 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,110 in 97 payments from 14 companies in 2025. Trend: 2023 $203 · 2024 $1,324 · 2025 $2,110
Food & beverage: $2,106Education: $4
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $465 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $276 |
| Vanda Pharmaceuticals Inc. | 7 | $275 |
| ABBVIE INC. | 14 | $232 |
| Otsuka America Pharmaceutical, Inc. | 9 | $190 |
| Teva Pharmaceuticals USA, Inc. | 8 | $156 |
| Lundbeck LLC | 4 | $110 |
| Janssen Pharmaceuticals, Inc | 4 | $82 |
| E.R. Squibb & Sons, L.L.C. | 5 | $78 |
| Collegium Pharmaceutical, Inc. | 4 | $73 |
Products named: ARISTADA, CAPLYTA, FANAPT, REXULTI, VRAYLAR, AUSTEDO XR, LYBALVI, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
